A review of prior screening mammograms of patients diagnosed with breast cancer allowed for the retrospective identification of previously missed tumors.
FDA grants Breakthrough Therapy designation for ribociclib as an initial endocrine-based therapy for HR+/HER2- breast cancer in premenopausal or perimenopausal women.
Patients with hormone receptor-positive, HER2-negative, axillary lymph node-negative breast cancer who have a recurrence score of 11 to 25 may not benefit from chemotherapy.
Interim joint analysis of the ABC Trials showed invasive disease-free survival was significant for superiority of anthracycline/taxane-based chemotherapy regimens (TaxAC) relative to docetaxel plus cyclophosphamide, according to study results presented at the 2016 ASCO Annual Meeting.
The experimental drug nintedanib, in combination with standard paclitaxel chemotherapy, caused a total remission of tumors in half of patients with early stage HER2-negative breast cancer.
Evidence-based recommendations have been developed for chemotherapy and targeted therapy for women with HER2-negative advanced breast cancer.
A test of tumor microenvironment of metastasis (TMEM) predicted risk of distant metastasis in estrogen receptor-positive and HER2-negative breast cancer, according to a new study.
High intake of saturated fat increases risk of HER2-negative, ER/PR-positive disease.
Adding dasatinib to the standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer. These results of a phase 2 clinical trial were presented at the 2013 San Antonio Breast Cancer Symposium.
Adding the antibody therapy ramucirumab to docetaxel therapy did not delay disease progression for patients with HER2-negative, advanced breast cancer. These results, from a placebo-controlled, randomized, phase 3 clinical trial, were presented at the 2013 San Antonio Breast Cancer Symposium.
